Studies to Assess the Utility of Serum Neurofilament Light Chain as a Biomarker in Chemotherapy-Induced Peripheral Neuropathy

被引:13
作者
Cavaletti, Guido [1 ,2 ]
Pizzamiglio, Chiara [3 ,4 ]
Man, Albert [5 ]
Engber, Thomas M. [5 ]
Comi, Cristoforo [3 ]
Wilbraham, Darren [5 ]
机构
[1] Univ Milano Bicocca, Sch Med & Surg, Expt Neurol Unit, I-20900 Monza, Italy
[2] Fdn IRCCS San Gerardo Tintori, I-20900 Monza, Italy
[3] Univ Piemonte Orientale, Dept Translat Med, I-28100 Novara, Italy
[4] UCL Queen Sq Inst Neurol, Natl Hosp Neurol & Neurosurg, Dept Neuromuscular Dis, London WC1N 3BG, England
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
关键词
chemotherapy-induced peripheral neuropathy; neurofilament light chain; paclitaxel; cancer; dose-limiting toxicity; NEUROTOXICITY; PREVALENCE; VALIDATION; SCORE; PAIN;
D O I
10.3390/cancers15174216
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Since neuroaxonal damage and loss are observed in chemotherapy-induced peripheral neuropathy (CIPN) and results in permanent disability, detecting and monitoring neuropathy with a serum biomarker would be advantageous in identifying the development, severity, and resolution of CIPN. We report here the results of two separate non-interventional studies (49 patients) that evaluated blood neurofilament light chain (NfL) as a biomarker of CIPN in breast cancer patients treated with paclitaxel. NfL was measured in serum using an ultrasensitive single-molecule array and compared with the self-administered European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN twenty-item scale (CIPN20) and Total Neuropathy Score clinical version (TNSc), a clinician-reported measure of neuropathy progression. Both NfL and TNSc were associated with the cumulative dose of chemotherapy and CIPN20 sensory subscore after chemotherapy. These findings provided evidence that serum NfL in breast cancer patients treated with chemotherapy has the potential to be used as a biomarker to monitor and mitigate CIPN, although studies with additional patients planned in the ongoing clinical trial will determine the universal application of NfL as a biomarker in CIPN.Abstract Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common and disabling dose-limiting toxicities of chemotherapy. We report here the results of two separate non-interventional studies (49 patients), which evaluated blood neurofilament light chain (NfL) as a biomarker of CIPN in breast cancer patients treated with paclitaxel. All patients underwent a standard treatment protocol that was established independently of the present studies. NfL was measured in serum using an ultrasensitive single-molecule array and compared with the self-administered European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN twenty-item scale (CIPN20) and Total Neuropathy Score clinical version (TNSc), a clinician-reported measure of neuropathy progression. The TNSc increased with cumulative dose compared with baseline, and the NfL concentrations were also strongly associated with the cumulative dose of chemotherapy. The analysis showed a correlation between TNSc and NfL. Both TNSc and NfL showed weak to moderate associations with CIPN20 subscores, with a better association for the CIPN20 sensory compared with motor and autonomic subscores. Data from the two studies provide evidence that serum NfL has the potential to be used as a biomarker to monitor and mitigate CIPN. However, studies with additional patients planned in the ongoing clinical trial will determine the universal application of NfL as a biomarker in CIPN.
引用
收藏
页数:16
相关论文
共 50 条
[31]   Cationic Nanoparticles Mitigate Chemotherapy-Induced Peripheral Neuropathy [J].
Bhansali, Divya ;
Latorre, Rocco ;
Tonello, Raquel ;
Poolman, David ;
Ding, Suwan ;
Schmidt, Brian L. ;
Bunnett, Nigel W. ;
Leong, Kam W. .
ADVANCED NANOBIOMED RESEARCH, 2025,
[32]   Chemotherapy-induced peripheral neuropathy [J].
Bushra Malik ;
Mark Stillman .
Current Pain and Headache Reports, 2008, 12
[33]   Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties [J].
Griffith, Kathleen A. ;
Merkies, Ingemar S. J. ;
Hill, Elizabeth E. ;
Cornblath, David R. .
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2010, 15 (04) :314-325
[34]   Recent advances in managing chemotherapy-induced peripheral neuropathy: A systematic review [J].
Wang, Mian ;
Pei, Ziwen ;
Molassiotis, Alex .
EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2022, 58
[35]   Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancers [J].
Kim, Su-Hyun ;
Kim, Ki Hoon ;
Hyun, Jae-Won ;
Kim, Ji Hyun ;
Seo, Sang-Soo ;
Kim, Ho Jin ;
Park, Sang-Yoon ;
Lim, Myong Cheol .
FRONTIERS IN ONCOLOGY, 2022, 12
[36]   Lipid signaling in chemotherapy-induced peripheral neuropathy [J].
Yamamoto, Shota ;
Egashira, Nobuaki .
CURRENT OPINION IN TOXICOLOGY, 2021, 28 :1-6
[37]   Chemotherapy-induced peripheral neuropathy and rehabilitation: A review [J].
Zhang, Shangming .
SEMINARS IN ONCOLOGY, 2021, 48 (03) :193-207
[38]   Chemotherapy-Induced Peripheral Neuropathy and Changes in Cytoskeleton [J].
Malacrida, Alessio ;
Meregalli, Cristina ;
Rodriguez-Menendez, Virginia ;
Nicolini, Gabriella .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (09)
[39]   Falls in persons with chemotherapy-induced peripheral neuropathy [J].
Tofthagen, Cindy ;
Overcash, Janine ;
Kip, Kevin .
SUPPORTIVE CARE IN CANCER, 2012, 20 (03) :583-589
[40]   Melittin, a honeybee venom derived peptide for the treatment of chemotherapy-induced peripheral neuropathy [J].
Tender, Tenzin ;
Rahangdale, Rakesh Ravishankar ;
Balireddy, Sridevi ;
Nampoothiri, Madhavan ;
Sharma, K. Krishna ;
Raghu Chandrashekar, Hariharapura .
MEDICAL ONCOLOGY, 2021, 38 (05)